US2013177663A1PendingUtilityA1

Bacteriocins and Novel Bacterial Strains

54
Individually held — no corporate assignee on recordPriority: May 1, 2003Filed: Jun 26, 2012Published: Jul 11, 2013
Est. expiryMay 1, 2023(expired)· nominal 20-yr term from priority
Inventors:Norman J. SternEdward A. SvetochNikolay N. UrakovBoris V. EruslanovLarisa I. VolodinaYuri N. KovalevTamara Y. KudryavtsevaVladimir V. PerelyginVictor D. PokhilenkoVladimir P. LevchukValery N. BorzenkovOlga E. SvetochEugeni V. MitsevichIrina P. Mitsevich
A61P 31/04A61P 1/00C07K 14/195C07K 14/32A23K 20/147A61K 38/00A23K 20/195A23L 33/127A23K 50/75A23K 10/10C12N 1/20A23K 1/006
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Novel bacteriocins produced by novel bacterial strains are used for at least reducing the levels of colonization by at least one target bacteria in animals, especially poultry.

Claims

exact text as granted — not AI-modified
1 - 5 . (canceled) 
     
     
         6 . An isolated  Paenibacillus polymyxa  having the identifying characteristics of a  Paenibacillus  strain-selected from the group consisting of NRRL B-30507, NRRL B-30508, and NRRL B-30509. 
     
     
         7 - 12 . (canceled) 
     
     
         13 . A therapeutic composition comprising:
 (a) at least one isolated bacteriocin having an amino acid sequence selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO. 3, and mixtures thereof in amounts effective to at least reduce the levels of colonization by at least one target bacteria, and   (b) a therapeutically acceptable carrier.   
     
     
         14 . A therapeutic feed for animals comprising:
 (a) at least one isolated bacteriocin produced by a  Paenibacillus polymyxa  strain having the identifying characteristics of a strain selected from the group consisting of NRRL B-30507, NRRL B-30508, and mixtures thereof in amounts effective to at least reduce the levels of colonization by at least one target bacteria,   (b) a therapeutic carrier, and   (c) an animal feed.   
     
     
         15 . (canceled) 
     
     
         16 . A therapeutic feed for animals comprising:
 (a) An isolated bacteriocin produced by a  Bacillus circulans  strain having the identifying characteristics of NRRL B-30644 in amounts effective to at least reduce the levels of colonization by at least one target bacteria,   (b) a therapeutic carrier, and   (c) an animal feed.   
     
     
         17 . (canceled) 
     
     
         18 . A therapeutic feed comprising:
 (a) at least one isolated bacteriocin produced by a microorganism selected from the group consisting of NRRL B-30507, NRRL B-30508, NRRL B-30509, and mixtures thereof in amounts effective to at least reduce the levels of colonization by at least one target bacteria,   (b) a therapeutic carrier, and   (c) an animal feed.   
     
     
         19 . A therapeutic animal feed comprising:
 (a) at least one isolated bacteriocin having an amino acid sequence selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3 and mixtures thereof in amounts effective to at least reduce the levels of colonization by at least one target bacteria,   (b) a therapeutic carrier, and   (c) an animal feed.   
     
     
         20 . A method for at least reducing the level of colonization by at least one target bacteria in an animal comprising:
 administering to an animal a therapeutic composition comprising at least one isolated bacteriocin produced by a  Paenibacillus polymyxa  bacteria having the identifying characterisitics of a strain selected from the group consisting of a NRRL B-30507, NRRL B-30508, NRRL B-30509, and mixtures thereof in amounts effective to at least reduce the levels of colonization by at least one target bacteria and a therapeutic carrier.   
     
     
         21 . The method of  claim 20  wherein said bacteriocin has an amino acid sequence selected from the group consisting of SEQ ID 1, SEQ ID 2, and mixtures thereof. 
     
     
         22 . A method for at least reducing the levels of colonization by at least one target bacteria in an animal comprising:
 administering to an animal a therapeutic composition comprising an isolated bacteriocin produced by a  Bacillus circulans  strain having the identifying characteristics of NRRL B-30644 in amounts effective to at least reduce the levels of colonization by at least one target bacteria in an animal and a therapeutic carrier.   
     
     
         23 . The method of  claim 22  wherein said bacteriocin has an amino acid sequence of SEQ ID NO 3. 
     
     
         24 . A method for at least reducing the levels of colonization by at least one target bacteria in an animal comprising:
 administering to an animal a therapeutic composition comprising at least one isolated bacteriocin produced by a microorganism selected from the group consisting of NRRL B-30507, NRRL B-30508, NRRL B-30509, NRRL B-30644, and mixtures thereof in amounts effective to at least reduce the levels of colonization of at least one target bacteria, and a therapeutic carrier.   
     
     
         25 . A method for at least reducing the levels of colonization by at least one target bacteria in an animal comprising:
 administering to an animal a therapeutic composition comprising at least one isolated bacteriocin having an amino acid sequence selected from the group consisting SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, and mixtures thereof in amounts effective to at least reduce the levels of colonization by at least one target bacteria and a therapeutic carrier.   
     
     
         26 . A therapeutic composition comprising:
 (a) an isolated bacteriocin having an amino acid sequence of SEQ ID NO 3 in amounts effective to at least reduce levels of colonization by at least one target bacteria, and   (b) a suitable therapeutic carrier.

Join the waitlist — get patent alerts

Track US2013177663A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.